← Sites

708 (USA)

USA PI: Dr. Kim activated KRI 0.1
Patients
32
Active (enrolled/consented)
0
Withdrawn
3
Serious AEs
0
Open QA findings
1
Aged data queries
0

Studies & contracts total budget 349000.00 USD

Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
Phase II study completed contract executed 349000 USD

Patients first 32

RefStatusConsentedStudy
708-1013 screened Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
708-1019 completed 2013-12-20 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
708-1032 completed 2013-02-09 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
708-1054 screened Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
708-1067 screened Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
708-1084 completed 2013-05-09 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
708-1087 completed 2012-10-22 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
708-1104 screened Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
708-1158 completed 2014-02-08 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
708-1171 completed 2012-12-06 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
708-1178 withdrawn 2013-12-29 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
708-1184 screened Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
708-1213 completed 2013-02-09 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
708-1216 completed 2012-10-24 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
708-1236 withdrawn 2013-09-21 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
708-1242 screened Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
708-1253 completed 2013-05-07 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
708-1272 withdrawn 2013-02-06 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
708-1286 completed 2013-09-10 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
708-1296 completed 2013-06-14 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
708-1297 completed 2013-01-25 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
708-1316 completed 2013-08-23 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
708-1336 completed 2012-12-07 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
708-1342 completed 2012-12-29 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
708-1347 completed 2013-04-20 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
708-1348 completed 2013-08-05 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
708-1352 screened Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
708-1353 completed 2013-07-04 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
708-1372 completed 2013-04-12 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
708-1378 completed 2013-09-03 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
708-1406 completed 2013-12-26 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
708-1428 completed 2013-11-09 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.

Luna participants (0)

No participants at this site use Luna yet.

Safety 102 AEs · 0 serious

No serious adverse events at this site.

QA findings 1 open

open major Protocol deviation

PROTOCOL VIOLATION: PROTOCOL ENTRY CRITERIA NOT MET (subject 708-1372, 2013-05-10)

Monitoring visits (0)

No visits recorded.

Payments (0)

No payments on file.